Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

INTRODUCTION: Pembrolizumab alone (IO-mono) or in combination with platinum-based chemotherapy (CT-IO) is first-line standard of care for advanced non-small cell lung cancer (NSCLC) patients with PD-L1 ≥ 50%. This retrospective multicentre study assessed real-world use and efficacy of both strategie...

Descripción completa

Detalles Bibliográficos
Autores principales: Pons-Tostivint, E., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., Veillon, R., Mayenga, M., Dumenil, C., Chatellier, T., Gourraud, P. A., Mazieres, J., Bennouna, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198917/
https://www.ncbi.nlm.nih.gov/pubmed/36690799
http://dx.doi.org/10.1007/s00262-022-03359-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198917/
https://www.ncbi.nlm.nih.gov/pubmed/36690799
http://dx.doi.org/10.1007/s00262-022-03359-2

Ejemplares similares